Category Archives: Genetic Medicine

Precision Medicine (PM) is an approach to disease prevention and treatment that seeks to maximize effectiveness by considering individual variability in genes, environment, and lifestyle, according to the Precision Medicine Initiative (PMI).1 After former President Obama announced the PMI in his State of the Union address on January 20, 2015to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthierthe National Health Institute and other global agencies commenced a group under the PMI called the PMI Cohort Program.

The goal of PM is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.2,3 Essential components of PM include the integration of information from several different sources, including genetic and genomic profiles, imaging data, records from wearable health-tracking devices and lifestyle choices, germline data, and pharmacogenomics. The access and application of these data and associated bioinformatics, using computing power and technological expertise to translate PM into personalized health care, are key.

For community practices, using PM will be greatly beneficial to patients and the practice. To maximize these benefits, PM needs to be integrated into the fabric of the community setting. All professionals in a practice will have to be involved in the development of a PM system, including physicians, pharmacists, lab personnel, nurses, and the patients. Although there have been obstacles to implementing diagnostic and screening tests, these can be overcome and will provide more options for patients with cancer.

Next-generation sequencing (NGS), which is rapidly replacing Sanger sequencing, has matured enough as a technology and found its place both in clinical practice and research. In addition, whole exome sequencing (WES) and/or whole genome sequencing (WGS) are becoming part of daily operation for oncologists and hematologists for exploring clinical trials and drug development for malignancies. The cost efficiency of NGS has improved significantly due to technological, scientific, and operational advances. The cost of deciphering the entire human genome has dropped from $10,000 in 2011 to approximately $1000 in 2021.4 Other drivers of PM include more accurate sequencing, a growing number of targeted therapies, and the recognition of biodiversity in the human genome especially in oncology and rheumatic illnesses.

Even in monetary aspects, the global market for PM is growing rapidly. Market research estimated the 2016 global market at $44 billion in revenue, and this revenue is forecast to more than triple to $140 billion by 2026.5

The rapid strides in sequencing techniques, bioinformatics, and PM have not been matched with efforts of implementation in day-to-day practice. Factors like integration into practice guidelines, lack of consensus and standardization between different stakeholders regarding minimum number of mutational analysis, germline studies, platforms for testing, and payer coverage threaten realization of PM.6

In addition to factors mentioned above, the biggest challenge for success in PM adoption is lack of diversity in the knowledge of genomics and bioinformatics in research and studies. Minority communities often face discrimination in health care and receive poor medical treatment.7 Outreach to these communities, especially in the research field, has also been characterized by a long history of exploitation, abuse, and marginalization.8 Although hesitancy from ethnic minorities is frequently cited as an excuse for the lack of representative data in PM and clinical trials, real-life observation is somewhat different, with researchers observing that willingness to participate did not differ significantly between ethno-racial groups.9 They also argued that underrepresentation of minority populations is more likely due to the research design of the study or limited accessibility.

Results from genome-wide association studies (GWAS) representing 1.7 million samples conducted in 2009 showed that 96% of participants were of European ancestry. Seven years later, the same GWAS analysis revealed that despite the colossal 35 million samples collected, 81% of participants were still of European ancestry. Clearly, racial and ethnic diversity of the samples still had a long way to go.10 The successful implementation of PM requires the clinical integration of the following (FIGURE 1):

With so many testing options, including NGS, WES, WGS, and whole transcriptome sequencing, healthcare providers now face a complex decision: whether to outsource this testing to centralized laboratories, implement it in their own labs, or create a hybrid model bringing part of the testing in house and using tertiary labs with full bioinformatics and sophisticated testing for thousands of genes for support. With the advent of NGS panels, genomic profiling has become leaner, cheaper, and more user friendly. Everything is quicker in house, with much less chance of losing important material or information. One of the best arguments for in-house genomic profiling is the control it affords over the preanalytical parameters, tissue specimen selection, and sample quality.

For many community oncologists, the latter option to create a collaborative model may enhance the uptake of appropriate molecular testing and address an unmet need, as most of the underserved, marginalized population is served by small- to medium-sized community cancer clinics. We must focus on doing those routine tests quickly, cost effectively, and as locally as possible in collaboration with tertiary labs that have additional testing capabilities and bioinformatics.

Additionally, centralized testing in a collaborative model is another very valuable option. When an FDA-approved treatment option is not available based on local minipanel testing results, additional testing with a much larger panel may provide options for clinical trials for new drug development. This testing may also identify germline mutations, such as BRCA1/2 or other homologous repair defects, and identify other family members at risk. This would allow others to implement appropriate clinical interventions to monitor their risk for disease. A bioinformatics platform will enhance assimilation of genomic, pharmacogenomics, and germline data to create a longitudinal journey and ultimately bring health care equity, address disparities, and enhance new drug developments. Benefits of insourcing NGS include the following (FIGURE 2):

In summary, even though the field of PM is still evolving and changing, driver mutation and biomarker-guided therapies have already improved treatment options for thousands of patients with cancer and thousands more are eligible for clinical trials. Because of limitations in access to overall testing, limited uptake of testingat the most, 25% in nonsmall cell lung cancer in Caucasians and 14% in ethnic minoritiesand skewed data disproportionately representative of Caucasians, the success of PM is not likely to be accomplished unless we explore different ways to approach testing. These include:

References:

1. National Institutes of Health. The Precision Medicine Initiative Cohort Program building a research foundation for 21st century medicine. September 17, 2015. Accessed April 19, 2021. https://bit.ly/2S4v8mF

2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795. doi:10.1056/NEJMp1500523

3. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-522.doi:10.1038/nrg.2016.86

4. Thermo Fisher Ion 520 DNA sequencing chip comparison and cost analysis report. ResearchAndMarkets.com. News release. February 9, 2018. Accessed April 27, 2021. https://bit.ly/3vimZcC

5. Global precision medicine market to reach $141.70 billion by 2026, reports BIS Research. BIS Research. News release. December 15, 2017. Accessed April 18, 2021. https://prn.to/3sYEwF6

6. Sholl LM, Aisner DL, Varella-Garcia M, et al; LCMC Investigators. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768-777. doi:10.1097/JTO.0000000000000516

7. Bhopal RS. Racism in health and health care in Europe: reality or mirage? Eur J Pub Health. 2007;17(3):238-241. doi:10.1093/eurpub/ckm039

8. Cohn EG, Henderson GE, Appelbaum PS. Distributive justice, diversity, and inclusion in precision medicine: what will success look like? Genet Med. 2017;19(2):157-159. doi:10.1038/gim.2016.92

9. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19. doi:10.1371/journal.pmed.0030019

10. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161-164. doi:10.1038/538161a

Originally posted here:
The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology - Targeted Oncology

New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management. Ms. Paul and Ms. Olson are both seasoned industry experts with extensive experience in the pharmaceutical and biotechnology industries including in the gene therapy and rare disease sectors.

"It is an exciting time at LogicBio with ongoing efforts to expand the reach of our GeneRide and sAAVy platforms validated by our recent collaboration deals with Daiichi Sankyo and CANbridge Pharmaceuticals. Adding key talent across the team is essential to our success and I look forward to working with Andrea and Janice, whose broad industry experience will be instrumental as we further strengthen our leadership position in the development of next-generation genetic medicines," said Frederic Chereau, president and chief executive officer of LogicBio Therapeutics.

Andrea Paul, General Counsel and Corporate Secretary

Ms. Paul joins LogicBio Therapeutics as general counsel and corporate secretary, effective May 17, 2021, bringing several years of experience in the pharmaceutical and biotechnology industries. She is currently at Akebia Therapeutics, Inc., where she has held roles of increasing responsibility, most recently serving as vice president, legal. While at Akebia, Ms. Paul was a key strategic legal partner in the company's merger with Keryx Biopharmaceuticals, Inc. as well as in the company's financing and business development transactions. Prior to Akebia, she served as senior corporate counsel at Momenta Pharmaceuticals, Inc. Before that, she was an associate at Mintz Levin and Sullivan & Cromwell LLP. She received her JD from Harvard Law School, where she served as the managing editor of the Harvard Law Review, and her BA from Columbia University (Columbia College). Ms. Paul currently serves as the co-chair of the Securities Law Committee of the Boston Bar Association.

"I am excited to be joining the executive team at LogicBio. The Company is deeply committed to patients, and I look forward to helping the team deliver the benefits of genetic medicine to the fight against early onset childhood diseases," said Ms. Paul.

Janice Olson, Senior Vice President, Strategy and Portfolio Management

Ms. Olson joins LogicBio Therapeutics as senior vice president, strategy and portfolio management, effective June 7, 2021. Previously, she spent more than 25 years at Genzyme (now Sanofi Genzyme) holding multiple roles, most recently serving as head of global medical affairs operations, starting in January 2016. Before that, Ms. Olson served as vice president of portfolio and program management for the Genzyme R&D center. During her time at Genzyme, she developed extensive experience managing and coordinating multi-disciplinary teams for numerous R&D projects from discovery through launch. She has also served as program lead for multiple gene therapy programs developed worldwide. Ms. Olson received her MBA and BS in biology from Northeastern University.

"I am thrilled to become part of LogicBio's amazing journey at such a transformative step of its development, and I am looking forward to helping the team and the Company's new strategic partners advance programs forward for patients with significant unmet needs," said Ms. Olson.

The Company also announced the resignation of Kyle Chiang, PhD, who will be stepping down as chief operating officer, effective May 28, 2021, to pursue an opportunity at a venture capital firm focusing on early-stage sustainability and life sciences focused ventures. Dr. Chiang will consult with the Company over the next several months to ensure a smooth transition.

"I would like to thank Kyle for his commitment over the early years of the Company and wish him the best as he enters a new field. With the additions announced today, we are further strengthening our leadership team, and I am confident we are well positioned to continue to expand our platforms and pipeline in the years ahead," added Mr. Chereau.

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit https://www.logicbio.com/.

Media Contacts:

Adam DaleyBerry & Company Public RelationsW: 212-253-8881C: 614-580-2048adaley@berrypr.com

Jenna UrbanBerry & Company Public RelationsW: 212-253-8881C: 203-218-9180jurban@berrypr.com

Investor Contacts:

Matt LaneGilmartin Group617-901-7698matt@gilmartinir.com

View original content:http://www.prnewswire.com/news-releases/logicbio-therapeutics-strengthens-management-team-with-key-appointments-301287264.html

SOURCE LogicBio Therapeutics, Inc.

Company Codes: NASDAQ-NMS:LOGC

Read this article:
LogicBio Therapeutics Strengthens Management Team with Key Appointments - BioSpace

Visit the News Hub

Study to look for genetic pathways that lead to formation of plaques, tangles

A $10.7 million, five-year grant will support a comprehensive study in which whole genome sequencing will be used to address critical gaps in knowledge about Alzheimer's disease. The project is led by researchers at Washington University School of Medicine in St. Louis and the University of Pittsburgh Graduate School of Public Health.

Despite decades of research and investment, the genetic underpinnings of Alzheimers disease are still largely unknown, stymieing efforts at drug development and early diagnosis. To change that, a new grant will support the first comprehensive study to use whole genome sequencing to address critical gaps in knowledge about the disease. The $10.7 million, five-year project is led by researchers at Washington University School of Medicine in St. Louis and the University of Pittsburgh Graduate School of Public Health.

Funded by the National Institute on Aging of the National Institutes of Health (NIH), the research team plans to identify the genetic variants, genes and pathways that lead to formation of plaques and tangles, two specific signs of disease called biomarkers that begin appearing in the brains of people with Alzheimers 15 to 25 years before they show symptoms.

Cruchaga

Genetic studies of measurable traits such as plaques and tangles provide advantages over other classic case-control studies, because these traits appear earlier and are more closely related to the biology behind the disease, said Carlos Cruchaga, PhD, a co-principal investigator of the study and the Reuben Morriss III Professor of Neurology at Washington University School of Medicine. In addition, studying these traits is more likely to lead to the identification of druggable targets along the genetic pathways that lead to disease. This genetic information can help us better predict disease risk at the individual patient level.

Cruchaga, also a professor of psychiatry, is working with co-principal investigator Ilyas Kamboh, PhD, a professor of human genetics and epidemiology at Pitt Public Health. Together, they plan to study as many as 5,000 participants at high risk for Alzheimers. The researchers will gather biomarker data to identify genetic variants that appear decades before clinical symptoms of the disease.

All of the clinical trials to find a drug to stop Alzheimers disease have failed because theyve focused on patients who already have developed the disease, so they already had high levels of plaques and tangles, said Kamboh. Once you have the plaques and tangles, it seems to be an irreversible process, so were focused on the preclinical stage of the disease.

According to the World Health Organization, Alzheimers disease is the most common form of dementia, with about 50 million cases worldwide and 6 million new cases each year. It is one of the major causes of disability and dependency among older people.

The plaques and tangles in the brain associated with Alzheimers can be thought of like cholesterol in the arteries of the heart and its association with heart disease, Kamboh explained. Cholesterol can quietly accumulate over years along the walls of the coronary arteries without causing symptoms until it causes a heart attack and does irreversible damage to the heart. Some genes predispose people to accumulate more cholesterol, and understanding that can allow people to take medication and make lifestyle changes that reduce the risk of heart disease. It also can prompt pharmaceutical companies to develop drugs that target the genetic pathways that lead to the formation of cholesterol deposits.

The new project will look for the genetic underpinnings of the plaques and tangles known to define Alzheimers disease and that formed due to abnormal accumulation of amyloid beta and tau proteins, respectively. Both can be detected early in the brains of living people through neuroimaging and the testing of cerebrospinal fluid.

In the past, we could detect these plaques and tangles only after death, through a brain autopsy, Kamboh said. Now we can identify them while people are living.

But those imaging and fluid-collection techniques are expensive and can be invasive.

New methods are now being developed to detect the presence of abnormal amyloid beta and tau proteins in less expensive blood tests, Cruchaga said. We hope that by learning more about the genes associated with the plaques and tangles, we might uncover underlying pathways that lead to Alzheimers disease and discover potential drug targets.

This study is supported by the National Institute on Aging of the National Institutes of Health (NIH). Grant number R01 AG064877.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Follow this link:
WashU, Pitt awarded $10.7 million for Alzheimer's disease research Washington University School of Medicine in St. Louis - Washington University...

A gene calledGAS2plays a key role in normal hearing, and its absence causes severe hearing loss, according to a study led by researchers in Penns Perelman School of Medicine.

The researchers, whose findings arepublished online inDevelopmental Cell, discovered that the protein encoded byGAS2is crucial for maintaining the structural stiffness of support cells in the inner ear that normally help amplify incoming sound waves. They showed that inner ear support cells lacking functionalGAS2lose their amplifier abilities, causing severe hearing impairment in mice. The researchers also identified people who haveGAS2mutations and severe hearing loss.

Anatomists 150 years ago took pains to draw these support cells with the details of their unique internal structures, but its only now, with this discovery aboutGAS2, that we understand the importance of those structures for normal hearing, says study senior authorDouglas J. Epstein, professor of genetics at Penn Medicine.

Two to three of every 1,000 children in the United States are born with hearing loss in one or both ears. About half of these cases are genetic. Although hearing aids and cochlear implants often can help, these devices seldom restore hearing to normal.

One of the main focuses of the Epstein laboratory at Penn Medicine is the study of genes that control the development and function of the inner eargenes that are often implicated in congenital hearing loss. The inner ear contains a complex, snail-shaped structure, the cochlea, that amplifies the vibrations from sound waves, transduces them into nerve signals, and sends those signals toward the auditory cortex of the brain.

Read more at Penn Medicine News.

Visit link:
Discovery of a new genetic cause of hearing loss illuminates how inner ear works | Penn Today - Penn Today

Gene therapy has shown promise in recent years for treating a range of diseases, including sickle-cell anemia, hemophilia, various forms of inherited blindness, mesothelioma, and Duchenne muscular dystrophy. A new success story may soon be added to this list, with the publication yesterday of the outcomes of a clinical trial that used gene therapy to cure a rare immune system disorder in infants.

The study, described in the New England Journal of Medicine, was carried out by researchers from UCLA and Great Ormond Street Hospital in London over the course of five years, beginning in 2012.

Adenosine deaminase (ADA) is an enzyme found in a type of white blood cell called lymphocytes, which are primarily active in the brain, GI tract, and thymus gland. Lymphocytes make antibodies and attack infected cells, so theyre pretty crucial to the immune system.

ADAs job is to convert a molecule thats harmful to lymphocytes into a non-harmful version of itself. If ADA cant work its magic, that molecule starts to build up in lymphocytes, becoming toxic and ultimately killing the cellsand leaving the immune system virtually defenseless, highly vulnerable to invaders like viruses and bacteria.

Mutations in the ADA gene mean the body doesnt make enough of the enzyme to successfully do its job. This deficiency of ADA leads to a condition called severe combined immunodeficiency (SCID). Those suffering from SCID can not only get sick very easily, but conditions that would be neutralized by a normal immune system quickly become deadly for them.

SCID was more commonly known as bubble boy disease after David Vetter, a boy born in Texas in 1971, spent 12 of his 13 years of life enclosed in a plastic bubble to protect him from germs.

About 20 different genetic mutations can cause SCID; ADA-SCID refers to immunodeficiency caused by lack of the ADA enzyme: severe combined immunodeficiency due to adenosine deaminase deficiencya bit of a mouthful. The worst part of ADA-SCID is that it occurs in babies; most are diagnosed with the condition before theyre even six months old, and without treatment they typically dont live past age two.

ADA is rare, estimated to occur in about 1 in 200,000 to 1,000,000 newborns worldwide; both the mothers and the fathers ADA gene must have mutations for the child to end up with this condition.

The first step in the gene therapy treatment was to collect hematopoietic stem cells, which are those that manufacture blood cells, from the patients. The researchers then inserted an intact copy of the ADA gene into the stem cells using an RNA virus called a lentivirus (the most well-known lentivirus is HIV).

The altered cells were re-injected into the patients, where they started producing ADA normally, yielding healthy immune cells.

Out of 50 total patients30 in the US and 20 in the UKwith ADA-SCID, 48 appear to have been rid of their condition thanks to the gene therapy, with no complications reported. The two patients who didnt have success with the therapy went back to traditional treatment methods, and didnt experience any adverse effects as a result of having tried the therapy.

If, or hopefully when, gene therapy becomes the go-to treatment for ADA-SCID, it will be a welcome reprieve from traditional options, which are neither pleasant nor cheap: patients need weekly injections of ADA until a bone marrow transplant can be done, and absent a donor, they must consistently receive injections, take antibiotics, and undergo antibody infusions for life.

If approved in the future, this treatment could be standard for ADA-SCID, and potentially many other genetic conditions, removing the need to find a matched donor for a bone marrow transplant and the toxic side effects often associated with that treatment, said Dr. Claire Booth, co-author of the study and a consultant in pediatric immunology and gene therapy at Londons Great Ormond Street Hospital.

Theres no mention of the cost of the therapy, nor whether this could be a prohibitive factor to making it a viable option. Nonetheless, the study is encouraging not just for its potential to revolutionize treatment of ADA-SCID, but as a harbinger for the promise of gene therapy for a multitude of genetic conditions.

People ask us, is it a cure? Who knows long term, but at least up to three years, these children are doing well, said Dr. Stephen Gottschalk, who was not involved in this study but performed a similar gene therapy on kids with SCID at St. Jude Childrens Research Hospital in Memphis. The immune function seems stable over time so I think it looks very, very encouraging.

Image Credit: liyuanalison from Pixabay

Read more:
How One Round of Gene Therapy Fixed 48 Kids' Immune Systems - Singularity Hub

BETHESDA, Md., May 13, 2021 /PRNewswire/ --The National Coordinating Center for the Regional Genetics Network (NCC) is excited to announce the second annual Public Health Genetics Week from May 24-28, 2021. The goal of Public Health Genetics Week is to increase awareness and to celebrate the field of public health genetics.

Each day of Public Health Genetics Week will have a different theme:

Individuals and organizations are encouraged to participate in the week by using the hashtags #PHGW and #PublicHealthGenetics across their social media platforms.

The following events will also occur throughout the week:

Ken Burns Presents The Gene: An Intimate HistoryVirtual Screening

In collaboration with WETA Washington, D.C., virtual daily screenings of Ken Burns Presents The Gene: An Intimate History ("THE GENE") will be held to celebrate Public Health Genetics Week. The landmark four-hour documentary seriesweaves together science, history, and personal stories to present a historical biography of the human genome, while also exploring groundbreaking breakthroughs for diagnosis and treatment of genetic diseases, and the complex web of moral, ethical and scientific questions raised by developments in genetics.

Listed below is the virtual screening schedule. More information, including registration information, can be found at https://phgw.org/thegene.

For more information about the film, visit https://pbs.org/thegene.

Social Media Events

Other Activities

OnPHGW.org, everyone can find more information about the daily themes, social media events, and social media tools (such as daily social media images, GIFs, social media banners, and more).

For questions or comments about Public Health Genetics Week, please contact [emailprotected]and be sure to follow NCC (@nccrcg) onFacebook,Instagram,LinkedIn,TikTok, andTwitterfor the latest updates on the week.

About the National Coordinating Center for the Regional Genetics Networks (NCC)

Funded since 2004 by the Health Resources and Services Administration/Maternal and Child Health Bureau (MCHB) to the American College of Medical Genetics and Genomics (ACMG), NCC's mission is to improve access to genetic services for underserved populations. In collaboration with the seven Regional Genetics Network (RGNs) and the National Genetics Education and Family Support Center (NGEFSC), NCC achieves this mission by working in the following focus areas: genetics and genomics education; genetics policy education; telemedicine; and data collection and evaluation. Learn more about the efforts of the NCC athttps://nccrcg.org.

NCC Funding Acknowledgement

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under Cooperative Agreement #UH9MC30770-01-00 from June 2020 to May 2024 for $800,000 per award year.

This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. government.

About Ken Burns Presents The Gene: An Intimate History

Ken Burns Presents The Gene: An Intimate Historyis a production of Florentine Films and WETA Washington, D.C., in association with Ark Media. Executive Producer and Senior Creative Consultant: Ken Burns. Written by Geoffrey C. Ward; and Barak Goodman & David Blistein. Based on the book "The Gene: An Intimate History" by Dr. Siddhartha Mukherjee. Narrator: David Costabile. Senior Producer: Barak Goodman. Directors: Chris Durrance and Jack Youngelson. Executive Producers: Dr. Siddhartha Mukherjee, Dalton Delan, Tom Chiodo, John F. Wilson and Anne Harrington. Production funding has been provided by Genentech, 23andMe, Cancer Treatment Centers of America, Alfred P. Sloan Foundation, Gray Foundation, American Society of Clinical Oncology (ASCO) & Conquer Cancer Foundation, Judy and Peter Blum Kovler Foundation, Craig and Susan McCaw Foundation, and the Corporation for Public Broadcasting. The Outreach and Education Partner is National Institutes of Health, National Human Genome Research Institute. Outreach support is provided by Foundation Medicine.

About WETA Washington, D.C.

WETA Washington, D.C., is a leading producer of new content for public television in the United States. WETA productions and co-productions include PBS NewsHour; Washington Week; documentaries by filmmaker Ken Burns, including Ken Burns Presents The Gene: An Intimate History, Cancer: The Emperor of all Maladies, Hemingway and the forthcoming MuhammadAli;and series and specials by scholar Henry Louis Gates, Jr., including Finding Your Roots, Reconstruction: America After the Civil War and The Black Church: This Is Our Story, This Is Our Song. WETA's multi-year campaign Well Beings addresses the critical health needs of Americans. More information on WETA and its programs and services is available at weta.org. On social media, visit facebook.com/wetatvfmon Facebook and follow @WETAtvfmon Twitter.

Related Images

image1.png

SOURCE National Coordinating Center for the Regional Genetics Networks (NCC)

Go here to see the original:
National Coordinating Center for the Regional Genetics Network (NCC) Announces the Second Annual Public Health Genetics Week, May 24-28, 2021 -...